Immunotherapy combo after transplant shows promise for High-Risk blood cancers
NCT ID NCT02681302
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to check for serious side effects and see how well the treatment worked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack University medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?